Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/95823
標題: Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin
作者: Chang, Yu-Chien
Lo, Wen-Jyi
Huang, Yu-Ting
Lin, Chaio-Lin
Feng, Chiu-Che
Lin, Hsin-Ting
鄭旭辰
Cheng, Hsu-Chen
Yeh, Su-Peng
關鍵字: AML
Ara-C
Deferasirox
doxorubicin
Antineoplastic Agents
Apoptosis
Benzoates
Cell Cycle
Cell Cycle Checkpoints
Cell Line, Tumor
Cell Proliferation
Cell Survival
Doxorubicin
Extracellular Signal-Regulated MAP Kinases
Humans
Iron
Leukemia
Phosphorylation
Reactive Oxygen Species
Triazoles
出版社: LEUKEMIA & LYMPHOMA
摘要: Deferasirox (DFX), in addition to its iron-chelation property, has marked anti-proliferative effects on cancer cells. However, the activity and mechanism by which DFX inhibits acute myeloid leukemia (AML) cells remain to be elucidated. Furthermore, the anti-leukemia effect of combining DFX with currently recommended agents doxorubicin (DOX) and cytosine arabinoside (Ara-C) has not been studied. In this study, we show that DFX significantly reduces the viability of three AML cell lines, HL60, THP1, and WEHI3 and two primary leukemic cells harvested from AML patients. DFX induces cell cycle arrest at G1 phase and apoptosis and inhibits phosphorylation of ERK. We also showed that DFX antagonizes the anti-leukemic effect of DOX. On the contrary, combining DFX with Ara-C created a synergistic effect. Our study confirms the anti-leukemia activity of DFX and provides important information on how to select a partner drug for DFX for the treatment of AML in future clinical trials.
URI: http://hdl.handle.net/11455/95823
Appears in Collections:生命科學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.